Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

- Siva, Shankar, Bressel, Mathias, Lin, Charles, Raman, Avi, Hardcastle, Nicholas, Hofman, Michael S., De Abreu Lourenco, Richard, Shaw, Mark, Mancuso, Pascal, Moon, Daniel, Wong, Lih-Ming, Lawrentschuk, Nathan, Sidhom, Mark, Wood, S, Brook, NR, Kron, T, Martin, Jarad, Pryor, D, FASTRACK II Investigator Group,, Sridharan, Swetha, Vanneste, Ben G. L., Davey, Ryan, Montgomery, Rebecca, Ruben, Jeremy, Foroudi, Farshad, Higgs, Braden

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

- Hofman, Michael S., Lawrentschuk, Nathan, Wong, Lih-Ming, Taubman, Kim, Ting Lee, Sze, Hsiao, Edward, Roach, Paul, Nottage, Michelle, Kirkwood, Ian, Hayne, Dickon, Link, Emma, Marusic, Petra, Francis, Roslyn J., Matera, A, Herschtal, A, Iravani, A, Hicks, RJ, Williams, S, Murphy, DG, Tang, Colin, Vela, Ian, Thomas, Paul, Rutherford, Natalie, Martin, Jarad M., Frydenberg, Mark, Shakher, Ramdave

Prostate cancer screening in primary health care: the current state of affairs

- Ranasinghe, Weranja K. B., Kim, Simon P., Lawrentschuk, Nathan, Papa, Nathan P., Sengupta, Shomik, Frydenberg, Mark, Bolton, Damien, Pond, Dimity, Ried, Karin, Marshall, Melanie J., Persad, Raj

Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy

- Ranasinghe, Weranja K.B., Attia, John, Oldmeadow, Christopher, Lawrentschuk, Nathan, Robertson, Jane, Ranasinghe, Tamra, Bolton, Damien, Persad, Raj